Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) shares soared in Wednesday afternoon’s trading, after putting the spotlight on its ongoing collaboration with Philips,
The Dutch electronics firm is to broaden its use of Polarean’s Xenon lung MRI technology to include younger children with chronic obstructive lung disease, subject to regulatory clearance.
Philips said it is integrating the Xenon MRI platform into its 3.0T MRI systems to support non-invasive, radiation-free imaging.
“By integrating the Xenon MRI platform into our advanced 3.0T MRI systems, we’re delivering a powerful, non-invasive tool that can transform how we diagnose, monitor, and manage chronic lung disease,” said Dr. Ioannis Panagiotelis, head of MRI at Philips.
In the statement, it was revealed that the technology enables clinicians to perform scans during two 10-second breath-holds without repositioning the patient, and, the scan session can be completed in under one minute.
“Philips and Polarean share a common goal: to make lung imaging more precise, accessible, and patient-friendly,” Polarean's chief executive, Dr. Christopher von Jako commented.
“The introduction of the XENOVIEW 3T Chest Coil, combined with Philips’ robust MRI platforms, marks a significant step in realising that vision.”
In London, Polarean shares were up 26% at 1.17p, after trading as high as 1.3p at one point in afternoon trading.